Literature DB >> 19793459

Clinical and pathologic features of cynomolgus macaques (Macaca fascicularis) infected with aerosolized Yersinia pestis.

Roger Van Andel1, Robert Sherwood, Chris Gennings, C Richard Lyons, Julie Hutt, Andrew Gigliotti, Ed Barr.   

Abstract

Since the anthrax attacks of 2001, the emphasis on developing animal models of aerosolized select agent pathogens has increased. Many scientists believe that nonhuman primate models are the most appropriate to evaluate pulmonary response to, vaccines for, and treatments for select agents such as Yersinia pestis (Y. pestis), the causative agent of plague. A recent symposium concluded that the cynomolgus macaque (Macaca fascicularis) plague model should be characterized more fully. To date, a well-characterized cynomolgus macaque model of pneumonic plague using reproducible bioaerosols of viable Y. pestis has not been published. In the current study, methods for creating reproducible bioaerosols of viable Y. pestis strain CO92 (YpCO92) and pneumonic plague models were evaluated in 22 Indonesian-origin cynomolgus macaques. Five macaques exposed to doses lower than 250 CFU remained free of any indication of plague infection. Fifteen macaques developed fever, lethargy, and anorexia indicative of clinical plague. The 2 remaining macaques died without overt clinical signs but were plague-positive on culture and demonstrated pathology consistent with plague. The lethal dose of plague in humans is reputedly less than 100 organisms; in this study, 66 CFU was the dose at which half of the macaques developed fever and clinical signs (ED(50)), The Indonesian cynomolgus macaque reproduces many aspects of human pneumonic plague and likely will provide an excellent model for studies that require a macaque model.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19793459      PMCID: PMC2703157     

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  28 in total

Review 1.  Humane endpoints for infectious disease animal models.

Authors:  E D Olfert; D L Godson
Journal:  ILAR J       Date:  2000

2.  Unusually high frequency MHC class I alleles in Mauritian origin cynomolgus macaques.

Authors:  Kendall C Krebs; ZheYuan Jin; Richard Rudersdorf; Austin L Hughes; David H O'Connor
Journal:  J Immunol       Date:  2005-10-15       Impact factor: 5.422

Review 3.  Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

Authors:  T V Inglesby; D T Dennis; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; A M Friedlander; J Hauer; J F Koerner; M Layton; J McDade; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; M Schoch-Spana; K Tonat
Journal:  JAMA       Date:  2000-05-03       Impact factor: 56.272

4.  LcrV plague vaccine with altered immunomodulatory properties.

Authors:  Katie A Overheim; R William Depaolo; Kristin L Debord; Elizabeth M Morrin; Debra M Anderson; Nathaniel M Green; Robert R Brubaker; Bana Jabri; Olaf Schneewind
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  Plague bacteria target immune cells during infection.

Authors:  Melanie M Marketon; R William DePaolo; Kristin L DeBord; Bana Jabri; Olaf Schneewind
Journal:  Science       Date:  2005-07-28       Impact factor: 47.728

6.  Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis.

Authors:  Anna N Honko; Nammalwar Sriranganathan; Cynthia J Lees; Steven B Mizel
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

7.  The effect of biphasic inhalation profiles on the deposition and clearance of coarse (6.5 microm) bolus aerosols.

Authors:  Andrew R Clark; Carole B Chambers; David Muir; Michael T Newhouse; Steven Paboojian; Carlos Schuler
Journal:  J Aerosol Med       Date:  2007

Review 8.  Yersinia pestis--etiologic agent of plague.

Authors:  R D Perry; J D Fetherston
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

9.  Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice.

Authors:  Sarah S Bubeck; Angelene M Cantwell; Peter H Dube
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

10.  Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen.

Authors:  A Roggenkamp; A M Geiger; L Leitritz; A Kessler; J Heesemann
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

View more
  12 in total

1.  Primary pneumonic plague in the African Green monkey as a model for treatment efficacy evaluation.

Authors:  R Colby Layton; Trevor Brasel; Andrew Gigliotti; Edward Barr; Steven Storch; Leslie Myers; Charles Hobbs; Frederick Koster
Journal:  J Med Primatol       Date:  2010-08-16       Impact factor: 0.667

2.  Characterization of full-length MHC class II sequences in Indonesian and Vietnamese cynomolgus macaques.

Authors:  Hannah M Creager; Ericka A Becker; Kelly K Sandman; Julie A Karl; Simon M Lank; Benjamin N Bimber; Roger W Wiseman; Austin L Hughes; Shelby L O'Connor; David H O'Connor
Journal:  Immunogenetics       Date:  2011-05-26       Impact factor: 2.846

3.  Milestones in progression of primary pneumonic plague in cynomolgus macaques.

Authors:  Frederick Koster; David S Perlin; Steven Park; Trevor Brasel; Andrew Gigliotti; Edward Barr; Leslie Myers; Robert C Layton; Robert Sherwood; C R Lyons
Journal:  Infect Immun       Date:  2010-04-12       Impact factor: 3.441

4.  A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.

Authors:  Jian Sha; Michelle L Kirtley; Curtis Klages; Tatiana E Erova; Maxim Telepnev; Duraisamy Ponnusamy; Eric C Fitts; Wallace B Baze; Satheesh K Sivasubramani; William S Lawrence; Igor Patrikeev; Jennifer E Peel; Jourdan A Andersson; Elena V Kozlova; Bethany L Tiner; Johnny W Peterson; David McWilliams; Snehal Patel; Eric Rothe; Vladimir L Motin; Ashok K Chopra
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

5.  The African Green Monkey Model of Pneumonic Plague and US Food and Drug Administration Approval of Antimicrobials Under the Animal Rule.

Authors:  Judith A Hewitt; Lynda L Lanning; Joseph L Campbell
Journal:  Clin Infect Dis       Date:  2020-05-21       Impact factor: 9.079

6.  Plague in Guinea pigs and its prevention by subunit vaccines.

Authors:  Lauriane E Quenee; Nancy Ciletti; Bryan Berube; Thomas Krausz; Derek Elli; Timothy Hermanas; Olaf Schneewind
Journal:  Am J Pathol       Date:  2011-03-04       Impact factor: 4.307

7.  Genomic sequencing and characterization of cynomolgus macaque cytomegalovirus.

Authors:  Angie K Marsh; David O Willer; Aruna P N Ambagala; Misko Dzamba; Jacqueline K Chan; Richard Pilon; Jocelyn Fournier; Paul Sandstrom; Michael Brudno; Kelly S MacDonald
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

8.  Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague.

Authors:  Claire A Cornelius; Lauriane E Quenee; Katie A Overheim; Frederick Koster; Trevor L Brasel; Derek Elli; Nancy A Ciletti; Olaf Schneewind
Journal:  Infect Immun       Date:  2008-09-15       Impact factor: 3.441

9.  Levofloxacin cures experimental pneumonic plague in African green monkeys.

Authors:  Robert Colby Layton; William Mega; Jacob D McDonald; Trevor L Brasel; Edward B Barr; Andrew P Gigliotti; Frederick Koster
Journal:  PLoS Negl Trop Dis       Date:  2011-02-08

10.  Model systems to study plague pathogenesis and develop new therapeutics.

Authors:  Matthew B Lawrenz
Journal:  Front Microbiol       Date:  2010-11-04       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.